Literature DB >> 26100659

Quality assessment of the guidelines on cystic neoplasms of the pancreas.

Massimo Falconi1, Stefano Crippa1, Suresh Chari2, Kevin Conlon3, Sun-Whe Kim4, Philippe Levy5, Masao Tanaka6, Jens Werner7, Christopher L Wolfgang8, Raffaele Pezzilli9, Carlos Fernandez-Del Castillo10.   

Abstract

BACKGROUND: Though cystic pancreatic neoplasms (CPNs) are being increasingly detected, their evaluation and management are still debated and have lead to publication of multiple guidelines for diagnostic work-up, indications for resection, and non-operative management with follow-up strategies of CPNs. AIMS: To analyze available guidelines in order to evaluate their overall quality and clinical applicability, indications for surgical resection and its extent, modalities and timing of follow-up when non-operative management is indicated.
METHODS: After a systematic search of the English literature, we selected eight guidelines for assessment according to the Appraisal of Guidelines, Research and Evaluation in Europe (AGREE) II instrument.
RESULTS: One guideline received the lower AGREE score regarding the "scope and purpose", "rigor of development" and "clarity and presentation" domains, whereas one received the best score for "stakeholder involvement" domain. No differences were found among different guidelines regarding the "applicability". The overall quality assessment score showed that only two guidelines were significantly lower than the others. According to the practical utilization recommendation score, four guidelines were considered as having full applicability in clinical practice.
CONCLUSION: Existing guidelines provide adequate guidance, at least with the present knowledge, for the management of cystic pancreatic lesions; however, not any one was satisfactory to all aspects related to the management of CPN. An update of the existing guidelines should be considered if and when more evidence-based data are available.
Copyright © 2015 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ADAPTE method; AGREE instrument; Diagnosis; Follow-up; Mucinous cystic neoplasm; Pancreatic cystic lesions

Mesh:

Year:  2015        PMID: 26100659     DOI: 10.1016/j.pan.2015.05.478

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  4 in total

1.  Are Clinical Guidelines for the Management of Intraductal Papillary Mucinous Neoplasms Followed?: A Single-Center Analysis.

Authors:  Parissa Tabrizian; Yaniv Berger; Elisa Sefora Pierobon; Samantha Aycart; Pamela Argiriadi; Kezhen Fei; Gonzalo Carrasco-Avino; Daniel M Labow; Umut Sarpel
Journal:  Pancreas       Date:  2017-02       Impact factor: 3.327

Review 2.  Treatment of branch-duct intraductal papillary mucinous neoplasms of the pancreas: state of the art.

Authors:  Stefano Crippa; Alessandra Piccioli; Maria Chiara Salandini; Chiara Cova; Francesca Aleotti; Massimo Falconi
Journal:  Updates Surg       Date:  2016-08-08

3.  McCune Albright syndrome is a genetic predisposition to intraductal papillary and mucinous neoplasms of the pancreas associated pancreatic cancer in relation with GNAS somatic mutation - a case report.

Authors:  Sébastien Gaujoux; Eric Pasmant; Caroline Silve; Nadia Mehsen-Cetre; Romain Coriat; Alexandre Rouquette; Bertrand Douset; Frédéric Prat; Karen Leroy
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

4.  Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.

Authors:  Michael Goggins; Kasper Alexander Overbeek; Randall Brand; Sapna Syngal; Marco Del Chiaro; Detlef K Bartsch; Claudio Bassi; Alfredo Carrato; James Farrell; Elliot K Fishman; Paul Fockens; Thomas M Gress; Jeanin E van Hooft; R H Hruban; Fay Kastrinos; Allison Klein; Anne Marie Lennon; Aimee Lucas; Walter Park; Anil Rustgi; Diane Simeone; Elena Stoffel; Hans F A Vasen; Djuna L Cahen; Marcia Irene Canto; Marco Bruno
Journal:  Gut       Date:  2019-10-31       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.